We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Hospital Acquired Infections Testing Kits Market to Reach USD 1.8 Billion by 2026

By LabMedica International staff writers
Posted on 08 Apr 2022
Print article
Image: Global HAI testing kits market will be driven by increased chronic diseases (Photo courtesy of Unsplash)
Image: Global HAI testing kits market will be driven by increased chronic diseases (Photo courtesy of Unsplash)

The global hospital acquired infections testing kits market is expected to grow at a CAGR of 12.7% from USD 1.12 billion in 2021 to USD 1.27 billion in 2022 and is projected to grow further at a CAGR of 8.8% to USD 1.78 billion in 2026, driven by increased incidence of chronic diseases. The rates of hospital acquired infection are higher among patients with increased susceptibility due to old age and underlying chronic diseases, such as COVID-19.

These are the latest findings of The Business Research Company (London, UK), a market intelligence firm.

The unprecedented coronavirus outbreak has caused a surge in the demand for hospital acquired infections testing kits, due to the rise in hospital acquired infections during the pandemic. The pandemic has raised enormous concerns over the quality of care in hospitals, due to the rising number of patients during COVID-19 and the change in staffing numbers. Multiple hospitals have experienced an increase in staffing levels, with traveling nurses reporting that these nurses were unfamiliar with hospital infection control processes. Such circumstances have made it difficult for hospitals to maintain patient safety and quality of care.

Increasing healthcare expenditure is predicted to drive a surge in the demand for hospital acquired infections testing kits. The growth in healthcare expenditure is aiding governments and organizations to spend more on prescription drugs, hospitals, and physical & clinical services, thereby driving the hospital acquired infections testing kits market. Consequently, the rise in healthcare spending will continue to drive an increase in the demand for hospital acquired infections testing kits in the near future.

Geographically, North America held the largest share of 36.2% of the global hospital acquired infections testing kits market in 2021, followed by the Asia-Pacific and other regions. Going forward, South America, Africa and the Middle East will be the world’s fastest-growing markets for hospital acquired infections testing kits with a CAGR of 9.3%, 8.8% and 8.8%, respectively, followed by the Asia Pacific and Western Europe.

Related Links:
The Business Research Company 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.